RecruitingPhase 2NCT06815666

BAL Fluid Biomarkers in Sarcoma

Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas

Sponsor

University Health Network, Toronto

Enrollment

70 participants

Start Date

Jan 29, 2025

Study Type

INTERVENTIONAL

Conditions

Soft Tissue Sarcoma (STS)Bronchoalveolar Lavage (BAL)Bronchoalveolar Lavage Fluid

Summary

This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting fluid samples from the lungs (called bronchoalveolar lavage, or BAL fluid) from patients with soft tissue sarcoma who are having lung surgery to remove tumors. The goal is to analyze biological markers in this lung fluid to better understand how sarcoma spreads to the lungs and to develop new tools to detect or treat it earlier. **You may be eligible if...** - You are 18 or older - You have been diagnosed with soft tissue sarcoma - You are scheduled for lung surgery (resection of a lung lesion) as part of your standard care **You may NOT be eligible if...** - You have had another invasive cancer in the past 2 years (except non-melanoma skin cancer or cancers that have been fully treated with no signs of return) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.